(Boursier.com) — Cellectis a clinical-stage biotechnology company using its pioneering TALEN genome editing technology to develop potential innovative therapies for the treatment of serious diseases, will present its first preliminary data exploring new TALEN editing processes in stem cells and hematopoietic progenitors (CSPHs) at the American Society of Gene and Cell Therapy (ASGCT), which will be held from May 7 to 11, 2024.
“These two posters illustrate the potential and versatility of TALEN technology to promote efficient insertion of genes into HSPCs. We demonstrate that single-stranded circular DNA molecules can be integrated into the genome of HSPCs with high efficiency and unprecedented precision and confirm that this process does not compromise the viability and differentiation capacity of the modified cells” commented Julien Valton, Ph.D., Vice President Gene Therapy at Cellectis.
“On the other hand, we illustrate a novel TALEN-mediated DNA insertion approach that exploits and redirects the natural ability of myeloid cells to cross the blood-brain barrier to efficiently vector a genetically encoded therapeutic protein into the brain. This “The approach is, in essence, versatile and could be used to vectorize a set of therapeutic proteins to the brain and potentially treat multiple neurological disorders.”
©2024 Boursier.com